Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 440,450
  • Shares Outstanding, K 64,677
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,210 K
  • 60-Month Beta -0.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.94
Trade TERN with:

Options Overview Details

View History
  • Implied Volatility 92.58% ( -15.18%)
  • Historical Volatility 93.55%
  • IV Percentile 11%
  • IV Rank 18.25%
  • IV High 313.50% on 05/31/24
  • IV Low 43.25% on 05/21/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 882
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 13,126
  • Open Int (30-Day) 10,161

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.35
  • Number of Estimates 4
  • High Estimate -0.32
  • Low Estimate -0.37
  • Prior Year -0.25
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.72 +17.83%
on 06/04/24
8.41 -19.90%
on 06/13/24
+0.73 (+12.15%)
since 05/31/24
3-Month
4.32 +56.02%
on 04/19/24
8.41 -19.90%
on 06/13/24
-0.36 (-5.07%)
since 04/01/24
52-Week
3.26 +106.75%
on 11/10/23
8.75 -22.97%
on 07/03/23
-2.01 (-22.97%)
since 06/30/23

Most Recent Stories

More News
This Small-Cap Biotech Could Gain Over 165%, Says Wall Street

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing drugs to combat obesity. Is TERN stock a good buy right now?

TERN : 6.71 (-1.47%)
VKTX : 56.56 (+6.70%)
LLY : 913.12 (+0.85%)
NVO : 145.15 (+1.69%)
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?

Madrigal's Rezdiffra will have the NASH market all to itself -- at least for a while.

GALT : 2.33 (+3.10%)
GLMD : 0.2800 (+1.82%)
VKTX : 56.56 (+6.70%)
ETNB : 7.84 (-2.12%)
IVA : 2.93 (-2.01%)
SGMT : 3.29 (-3.80%)
TERN : 6.71 (-1.47%)
NVO : 145.15 (+1.69%)
IQV : 210.39 (-0.50%)
MDGL : 278.69 (-0.52%)
3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

NASH treatments are projected to be one of the most sought-after indications in the coming years.

MDGL : 278.69 (-0.52%)
TERN : 6.71 (-1.47%)
VKTX : 56.56 (+6.70%)
Looking for the Next Big Biopharma Stock? These 4 Letters Are 1 Big Clue Where to Find It

NASH is a surprisingly common ailment, and the first treatments are on the way.

GILD : 68.92 (+0.45%)
NVO : 145.15 (+1.69%)
LLY : 913.12 (+0.85%)
TERN : 6.71 (-1.47%)
VKTX : 56.56 (+6.70%)
MDGL : 278.69 (-0.52%)
Why Shares of Terns Pharmaceuticals Soared This Week

The company is showing progress toward a NASH therapy.

NVS : 106.61 (+0.14%)
TERN : 6.71 (-1.47%)
Pre-Market Brief: Stocks Mostly Lower as Economic Outlook Darkens, BoJ Policy Shift

March S&P 500 futures (ESH23) are trending down -0.08% this morning after three major U.S. benchmark indices closed lower for a fourth straight session, with Nasdaq dropping the most as market participants'...

ESH23 : 3,957.05s (-0.09%)
META : 498.64 (-1.11%)
ICCM : 0.7401 (+0.01%)
LCID : 2.65 (+1.53%)
SLNO : 41.33 (+1.30%)
TERN : 6.71 (-1.47%)
SMCI : 818.50 (-0.10%)
Terns Announces Appointment of Radhika Tripuraneni, M.D., M.P.H. to Board of Directors

FOSTER CITY, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

TERN : 6.71 (-1.47%)
Terns Pharmaceuticals Highlights Clinical Data from Multiple NASH Programs in Five Presentations at the EASL International Liver Congress™ 2022

-Oral presentation of data from Phase 1 first-in-human trial of TERN-501, demonstrating treatment was well-tolerated and resulted in significant...

TERN : 6.71 (-1.47%)
Terns Pharmaceuticals to Present Clinical Data on Multiple NASH Programs at the EASL International Liver Congress 2022

FOSTER CITY, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage...

TERN : 6.71 (-1.47%)
Terns Pharmaceuticals Appoints Kerry Russell as Chief Medical Officer

- Dr. Russell to report to Dr. Erin Quirk, President and Head of Research & Development FOSTER CITY, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Terns...

TERN : 6.71 (-1.47%)

Business Summary

Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY,...

See More

Key Turning Points

3rd Resistance Point 7.63
2nd Resistance Point 7.42
1st Resistance Point 7.11
Last Price 6.71
1st Support Level 6.59
2nd Support Level 6.38
3rd Support Level 6.07

See More

52-Week High 8.75
Last Price 6.71
Fibonacci 61.8% 6.65
Fibonacci 50% 6.01
Fibonacci 38.2% 5.36
52-Week Low 3.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar